INDUCTION OF IN-VITRO APOPTOSIS BY FLUDARABINE IN FRESHLY ISOLATED B-CHRONIC LYMPHOCYTIC-LEUKEMIA CELLS

被引：21

作者：

ZINZANI, PL

BUZZI, M

FARABEGOLI, P

TOSI, P

FORTUNA, A

VISANI, G

MARTINELLI, G

ZACCARIA, A

TURA, S

机构：

[1] Institute of Haematology L. e A. Seràgnoli, University of Bologna

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 13卷 / 1-2期

关键词：

FLUDARABINE; APOPTOSIS; B-CLL; MAFOSFAMIDE;

D O I：

10.3109/10428199409051657

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The cytotoxic effects and apoptosis (programmed cell death) induced by fludarabine (FLU), interleukin-2 (IL-2), interleukin-4 (IL-4), IL-2 plus IL-4, alpha-interferon (alpha-IFN), and mafosfamide were evaluated ''in vitro'' on freshly isolated B-cell chronic lymphocytic leukemia (B-CLL) cells. Cytotoxicity was evaluated according to the soluble tetrazolium/formazan assay. Treatment with mafosfamide, fludarabine, and IL-4 resulted in significant anti-tumor activity against all the freshly isolated samples. On the other hand, no significant cytotoxic activity was observed with alpha-IFN, IL-2, and the combination of IL-2 and IL-4. Apoptosis was evaluated by electrophoresis gel of DNA oligonucleosomal fragments and only FLU significantly activated apoptosis in all the samples. It appears that fludarabine is active against B-CLL cells acting by an direct cytotoxic effect and/or the induction of cell death by apoptosis.

引用

页码：95 / 97

页数：3

共 9 条

[1] Keating M.J., Kantarjian H., Talpaz M., Flu-darabine: a new agent with major activity against chronic lym-phocytic leukemia, Blood, 74, pp. 19-25, (1989)
[2] Hiddemann W., Rottmann R., Wormann B., Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase II study, Ann. Hematol., 63, pp. 1-4, (1991)
[3] Keating M.J., Kantarjian H., O'Brien S., Flu-darabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia, J. Clin. Oncol., 9, pp. 44-49, (1991)
[4] Zinzani P.L., Lauria F., Rondelli D., Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia, Eur. J. Hematol., (1993)
[5] Dow L.W., Bell D.E., Poulakos L., Differences in metabolism and cytotoxicity between 9-β-D-arabino-furanosyladenine and 9-β-D-arabinosyl-2-fluoroadenine in human leukemic lymphoblasts, Cancer Res., 40, pp. 1405-1410, (1980)
[6] Brockman R.W., Schabel F.M., Montgomery J.A., Biologic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabinofurano-syl-adenine, Biochem. Pharmacol., 26, pp. 2193-2196, (1977)
[7] Kerr J.F.R., Wyllie A.H., Currie A.R., Apop-tosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics, Br. J. Cancer, 26, pp. 239-257, (1972)
[8] Alley M.C., Scudiero D.A., Monks A., Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay, Cancer Res., 48, pp. 589-592, (1988)
[9] Zinzani P.L., Clark J.W., Kouttab N.M., Lymphokine-activated killer (LAK) activity using XTT-micro-culture tetrazolium assay against the melanoma MELTANG cell line, Immunity to Cancer, 14, (1989)

← 1 →